| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Byron Baron | Q51638904 |
| P2093 | author name string | Maria Portelli | |
| P2860 | cites work | Developmental roles of the histone lysine demethylases | Q22306162 |
| Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor | Q24294262 | ||
| Lysine methylation of VCP by a member of a novel human protein methyltransferase family | Q24298017 | ||
| Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family | Q24303496 | ||
| Regulation of p53 activity through lysine methylation | Q24311514 | ||
| Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor | Q24320710 | ||
| The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor | Q24328901 | ||
| The diverse members of the mammalian HSP70 machine show distinct chaperone-like activities | Q24336905 | ||
| Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor | Q24560244 | ||
| Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers | Q24605342 | ||
| Guidelines for the nomenclature of the human heat shock proteins | Q24653946 | ||
| EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells | Q24672969 | ||
| Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase | Q24674431 | ||
| The SET-domain protein superfamily: protein lysine methyltransferases | Q24811144 | ||
| Chemical probes of histone lysine methyltransferases | Q26829218 | ||
| Protein methylation at the surface and buried deep: thinking outside the histone box | Q27025874 | ||
| Structural origins for the product specificity of SET domain protein methyltransferases | Q27653167 | ||
| Chemogenetic analysis of human protein methyltransferases | Q27667805 | ||
| Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia | Q79903356 | ||
| Maternal plasma concentrations of soluble endoglin in pregnancies with intrauterine growth restriction | Q80140120 | ||
| Total cell-free DNA (beta-globin gene) distribution in maternal plasma at the second trimester: a new prospective for preeclampsia screening | Q80602749 | ||
| beta-globin DNA in maternal plasma as a molecular marker of pre-eclampsia | Q80602764 | ||
| ADAM12s in maternal serum as a potential marker of pre-eclampsia | Q80673251 | ||
| Circulating concentrations of soluble endoglin (CD105) in fetal and maternal serum and in amniotic fluid in preeclampsia | Q80774704 | ||
| Adhesion molecules changes at 20 gestation weeks in pregnancies complicated by preeclampsia | Q80812036 | ||
| Serum visfatin levels in late pregnancy and pre-eclampsia | Q80999389 | ||
| Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation | Q81429334 | ||
| Pre-eclampsia | Q81446389 | ||
| Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia | Q81475941 | ||
| First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of preterm or early preterm delivery | Q81575462 | ||
| Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsia | Q81813556 | ||
| Reduction of the disintegrin and metalloprotease ADAM12 in preeclampsia | Q81920292 | ||
| A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound | Q82068160 | ||
| Levels of asymmetric dimethylarginine throughout normal pregnancy and in pregnancies complicated with preeclampsia or had a small for gestational age baby | Q82092929 | ||
| Perfusion of human placenta with hemoglobin introduces preeclampsia-like injuries that are prevented by α1-microglobulin | Q83487574 | ||
| Expression of heat shock protein 70 and endothelial nitric oxide synthase in placental tissue of preeclamptic and intrauterine growth-restricted pregnancies | Q84242408 | ||
| Plasma placenta growth factor levels in midtrimester pregnancies | Q74567407 | ||
| Decreased first trimester PAPP-A is a predictor of adverse pregnancy outcome | Q74771276 | ||
| Increased circulating concentrations of asymmetric dimethyl arginine (ADMA), an endogenous inhibitor of nitric oxide synthesis, in preeclampsia | Q77425923 | ||
| Preeclampsia is associated with reduced serum levels of placenta growth factor | Q77690843 | ||
| Hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome as a complication of preeclampsia in pregnant women increases the amount of cell-free fetal and maternal DNA in maternal plasma and serum | Q77785524 | ||
| Structure, expression and receptor-binding properties of placenta growth factor (PlGF) | Q77808284 | ||
| Elevated soluble adhesion molecules in women with pre-eclampsia. Do cytokines like tumour necrosis factor-alpha and interleukin-1beta cause endothelial activation | Q78202117 | ||
| Is oxidative stress the link in the two-stage model of pre-eclampsia? | Q78258200 | ||
| Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences | Q79260245 | ||
| Hsp70 promotes antigen-presenting cell function and converts T-cell tolerance to autoimmunity in vivo | Q79305181 | ||
| Second- and third-trimester serum levels of placental proteins in preeclampsia and small-for-gestational age pregnancies | Q79369524 | ||
| First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of pre-eclampsia | Q79409207 | ||
| Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion | Q79685499 | ||
| Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia | Q79714247 | ||
| Second-trimester uterine artery Doppler pulsatility index and maternal serum PP13 as markers of pre-eclampsia | Q79719767 | ||
| First-trimester ADAM12 and PAPP-A as markers for intrauterine fetal growth restriction through their roles in the insulin-like growth factor system | Q79719770 | ||
| First-trimester maternal serum a disintegrin and metalloprotease 12 (ADAM12) and adverse pregnancy outcome | Q79772135 | ||
| Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia | Q79823183 | ||
| Low levels of maternal serum PAPP-A in the first trimester and the risk of pre-eclampsia | Q79829262 | ||
| Correlation between placental bed biopsy findings, vascular cell adhesion molecule and fibronectin levels in pre-eclampsia | Q73663153 | ||
| Decreased maternal serum placenta growth factor in early second trimester and preeclampsia | Q73953218 | ||
| Placental apoptosis in preeclampsia | Q74047219 | ||
| Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy | Q74090763 | ||
| Abruptio placentae. A "classic" dedicated to Elizabeth Ramsey | Q74108342 | ||
| Trophoblast apoptosis from pregnancies complicated by fetal growth restriction is associated with enhanced p53 expression | Q74115818 | ||
| Plasma concentrations of asymmetric dimethylarginine, a natural inhibitor of nitric oxide synthase, in normal pregnancy and preeclampsia | Q74434549 | ||
| Chromatin modifications and their function | Q27861067 | ||
| The ribosomal l1 protuberance in yeast is methylated on a lysine residue catalyzed by a seven-beta-strand methyltransferase | Q27933992 | ||
| Identification of a new endothelial cell growth factor receptor tyrosine kinase | Q28117368 | ||
| Primary, secondary, and tertiary prevention of pre-eclampsia | Q28176253 | ||
| Expression of vascular endothelial growth factor and placenta growth factor in human placenta | Q28235920 | ||
| Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR | Q28238949 | ||
| Placenta growth factor: identification and characterization of a novel isoform generated by RNA alternative splicing | Q28242600 | ||
| Soluble endoglin contributes to the pathogenesis of preeclampsia | Q28244053 | ||
| A heparin-binding form of placenta growth factor (PlGF-2) is expressed in human umbilical vein endothelial cells and in placenta | Q28251626 | ||
| Histone methylation: a dynamic mark in health, disease and inheritance | Q28263573 | ||
| Histone demethylases in development and disease | Q28293982 | ||
| Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14 | Q28297843 | ||
| Selenium-based S-adenosylmethionine analog reveals the mammalian seven-beta-strand methyltransferase METTL10 to be an EF1A1 lysine methyltransferase | Q28542486 | ||
| Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium | Q28587604 | ||
| Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain | Q28609769 | ||
| Histone methyltransferases in cancer | Q29042217 | ||
| Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis | Q29547178 | ||
| Mechanisms of angiogenesis | Q29547485 | ||
| The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine | Q29547539 | ||
| The polycomb group protein EZH2 is involved in progression of prostate cancer | Q29614514 | ||
| Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia | Q29615916 | ||
| The HSP70 chaperone machinery: J proteins as drivers of functional specificity | Q29616140 | ||
| Many paths to methyltransfer: a chronicle of convergence | Q29616667 | ||
| Protein arginine methylation in mammals: who, what, and why | Q29617309 | ||
| Arginine methylation an emerging regulator of protein function | Q29617311 | ||
| Angiogenesis as a therapeutic target | Q29619525 | ||
| SET domain protein lysine methyltransferases: Structure, specificity and catalysis. | Q30159622 | ||
| A newly uncovered group of distantly related lysine methyltransferases preferentially interact with molecular chaperones to regulate their activity | Q30179453 | ||
| Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies | Q31843148 | ||
| Structural and evolutionary bioinformatics of the SPOUT superfamily of methyltransferases | Q33276931 | ||
| Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion | Q33316902 | ||
| Microparticle-associated P-selectin reflects platelet activation in preeclampsia | Q33374589 | ||
| Maternal circulating levels of activin A, inhibin A, sFlt-1 and endoglin at parturition in normal pregnancy and pre-eclampsia | Q33438425 | ||
| Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase | Q33865641 | ||
| Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies | Q33930498 | ||
| Lysine methylation promotes VEGFR-2 activation and angiogenesis | Q33940384 | ||
| The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease | Q33940891 | ||
| Release of heat shock protein 70 and the effects of extracellular heat shock protein 70 on the production of IL-10 in fibroblast-like synoviocytes | Q37171027 | ||
| Elevated asymmetric dimethylarginine concentrations precede clinical preeclampsia, but not pregnancies with small-for-gestational-age infants | Q37181052 | ||
| Protein methylation: a new mechanism of p53 tumor suppressor regulation | Q37200670 | ||
| Serum levels of asymmetric dimethylarginine, vascular endothelial growth factor, and nitric oxide metabolite levels in preeclampsia patients | Q37206251 | ||
| Increased sFlt-1 to PlGF ratio in women who subsequently develop preeclampsia | Q37221219 | ||
| Potential markers of preeclampsia--a review | Q37278804 | ||
| Recent advances in the understanding of the pathophysiology of preeclampsia | Q37376964 | ||
| First-trimester maternal serum PP13 in the risk assessment for preeclampsia. | Q37444801 | ||
| Nitric oxide: an endogenous modulator of leukocyte adhesion | Q37519420 | ||
| Preeclampsia is associated with alterations in the p53-pathway in villous trophoblast | Q37534671 | ||
| Histone H3 lysine 4 (H3K4) methylation in development and differentiation | Q37585674 | ||
| Cell-Free Total and Fetal DNA in First Trimester Maternal Serum and Subsequent Development of Preeclampsia | Q37711864 | ||
| Histone lysine methylation and demethylation pathways in cancer | Q37800638 | ||
| Epigenetic regulation of aging stem cells | Q37858414 | ||
| Histone tails: Directing the chromatin response to DNA damage | Q37881417 | ||
| The diverse functions of Dot1 and H3K79 methylation. | Q37897061 | ||
| Review: Biochemical markers to predict preeclampsia | Q37971237 | ||
| Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics | Q38060521 | ||
| Tipping the lysine methylation balance in disease | Q38061868 | ||
| Histone lysine methylation dynamics: establishment, regulation, and biological impact | Q38064095 | ||
| Protein arginine methyltransferases and cancer | Q38067063 | ||
| Modulation of angiogenesis during adipose tissue development in murine models of obesity | Q38323635 | ||
| Critical roles of non-histone protein lysine methylation in human tumorigenesis | Q38329400 | ||
| Increased NFAT5 expression stimulates transcription of Hsp70 in preeclamptic placentas | Q39036761 | ||
| Enhanced HSP70 lysine methylation promotes proliferation of cancer cells through activation of Aurora kinase B. | Q39275975 | ||
| Study of plasma adrenomedullin level in normal pregnancy and preclampsia. | Q39446260 | ||
| The lysine 831 of vascular endothelial growth factor receptor 1 is a novel target of methylation by SMYD3. | Q40050639 | ||
| Heat shock proteins form part of a danger signal cascade in response to lipopolysaccharide and GroEL. | Q40263946 | ||
| Over-expression of 70-kDa heat shock protein confers protection against monochloramine-induced gastric mucosal cell injury | Q40313450 | ||
| The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma | Q40813288 | ||
| Colocalisation of vascular endothelial growth factor and its Flt-1 receptor in human placenta | Q41385756 | ||
| Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor. | Q42816830 | ||
| Calmodulin methyltransferase is an evolutionarily conserved enzyme that trimethylates Lys-115 in calmodulin | Q42847905 | ||
| Prevention of pre-eclampsia | Q43625987 | ||
| Plasma P-selectin is elevated in the first trimester in women who subsequently develop pre-eclampsia | Q43684244 | ||
| Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies | Q43991495 | ||
| Correlation of P-selectin and lipoprotein(a), and other lipid parameters in preeclampsia | Q44017351 | ||
| Hypoxia-reoxygenation: a potent inducer of apoptotic changes in the human placenta and possible etiological factor in preeclampsia. | Q44044678 | ||
| Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, in maternal and fetal circulation | Q44271946 | ||
| Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia | Q44434565 | ||
| Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine. | Q44545493 | ||
| Plasma concentrations of asymmetric dimethylarginine (ADMA) in Colombian women with pre-eclampsia | Q44768366 | ||
| Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes. | Q45295203 | ||
| Placental bed biopsies in placental abruption | Q45914319 | ||
| Asymmetric dimethylarginine in the maternal and fetal circulation in preeclampsia. | Q45937731 | ||
| Dietary L-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans. | Q46024028 | ||
| Financial impact of a novel pre-eclampsia diagnostic test versus standard practice: a decision-analytic modeling analysis from a UK healthcare payer perspective | Q46329159 | ||
| Pregnancy-related mortality from preeclampsia and eclampsia | Q46353535 | ||
| Reduced L-arginine level and decreased placental eNOS activity in preeclampsia. | Q46594772 | ||
| Determination of asymmetric dimethylarginine, an endogenous nitric oxide synthase inhibitor, in umbilical blood | Q46811532 | ||
| Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure | Q46861533 | ||
| Circulating angiogenic factors and the risk of preeclampsia | Q47217679 | ||
| Prospective analysis of placenta growth factor (PlGF) concentrations in the plasma of women with normal pregnancy and pregnancies complicated by preeclampsia | Q47674689 | ||
| First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). | Q47860634 | ||
| Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth | Q47864591 | ||
| First trimester maternal serum placental protein 13 for the prediction of pre-eclampsia in women with a priori high risk | Q47872838 | ||
| Two-stage elevation of cell-free fetal DNA in maternal sera before onset of preeclampsia. | Q47889241 | ||
| Insulin resistance and alterations in angiogenesis: additive insults that may lead to preeclampsia | Q47945074 | ||
| Receptors of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in fetal and adult human kidney: localization and [125I]VEGF binding sites | Q47989650 | ||
| Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award | Q48348609 | ||
| Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. | Q50775910 | ||
| First-trimester prediction of hypertensive disorders in pregnancy. | Q51775989 | ||
| Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. | Q51914188 | ||
| Altered expression of regulators of caspase activity within trophoblast of normal pregnancies and pregnancies complicated by preeclampsia. | Q51944536 | ||
| Molecular evidence of placental hypoxia in preeclampsia. | Q51975690 | ||
| Possible role of asymmetric dimethylarginine (ADMA) in prediction of perinatal outcome in preeclampsia and fetal growth retardation related to preeclampsia. | Q53192091 | ||
| Soluble endoglin as a second-trimester marker for preeclampsia. | Q53535438 | ||
| Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. | Q53600812 | ||
| Changes in serum levels of heat shock protein 70 in preterm delivery and pre-eclampsia. | Q53873089 | ||
| Predicting complications of pregnancy with first-trimester maternal serum free-betahCG, PAPP-A and inhibin-A. | Q53873373 | ||
| HSP70 is associated with endothelial activation in placental vascular diseases. | Q54540007 | ||
| THE LEVELS OF CIRCULATORY FETAL DNA IN MATERNAL PLASMA ARE ELEVATED PRIOR TO THE ONSET OF PREECLAMPSIA | Q56001888 | ||
| First Trimester Placental Growth Factor and Soluble Fms-Like Tyrosine Kinase 1 and Risk for Preeclampsia | Q56619507 | ||
| Elevated maternal levels of the long pentraxin 3 (PTX3) in preeclampsia and intrauterine growth restriction | Q56942827 | ||
| Performance of a panel of maternal serum markers in predicting preeclampsia at 11-15 weeks' gestation | Q56994317 | ||
| Elevation of both maternal and fetal extracellular circulating deoxyribonucleic acid concentrations in the plasma of pregnant women with preeclampsia | Q57671390 | ||
| Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia | Q58377198 | ||
| Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia | Q58778301 | ||
| Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines | Q59122859 | ||
| Increased placental apoptosis in pregnancies complicated by preeclampsia | Q59367145 | ||
| Placental apoptosis in normal human pregnancy | Q59367743 | ||
| Oxidative stress | Q59633631 | ||
| Plasma and Tissue Expression of the Long Pentraxin 3 During Normal Pregnancy and Preeclampsia | Q60609634 | ||
| Circulating microparticles: a marker of procoagulant state in normal pregnancy and pregnancy complicated by preeclampsia or intrauterine growth restriction | Q60947387 | ||
| Comparison of expression patterns for placenta growth factor, vascular endothelial growth factor (VEGF), VEGF-B and VEGF-C in the human placenta throughout gestation | Q61479347 | ||
| Localization of VEGF and expression of its receptors flt and KDR in human placenta throughout pregnancy | Q61484920 | ||
| Soluble adhesion molecule profile in normal pregnancy and pre-eclampsia | Q61845530 | ||
| Fetal hemoglobin and α1-microglobulin as first- and early second-trimester predictive biomarkers for preeclampsia | Q61848157 | ||
| Longitudinal Determination of Serum Placental Protein 13 during Development of Preeclampsia | Q61865449 | ||
| Occurrence of a new enzyme catalyzing the direct conversion of NG,NG-dimethyl-L-arginine to L-citrulline in rats | Q69464010 | ||
| Plasma P selectin (GMP-140) and glycocalicin are elevated in preeclampsia and eclampsia: their significances | Q70926330 | ||
| Localisation of placenta growth factor (PIGF) in human term placenta | Q71779652 | ||
| Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney | Q72564866 | ||
| Serum levels of heat shock protein 70 in patients with preeclampsia: a pilot-study | Q73039113 | ||
| First trimester maternal serum free beta human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications | Q73070066 | ||
| Increased maternal plasma fetal DNA concentrations in women who eventually develop preeclampsia | Q73371440 | ||
| Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia | Q73506827 | ||
| ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. | Q33990220 | ||
| Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine | Q34102413 | ||
| Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase | Q34145182 | ||
| Substrate and product specificities of SET domain methyltransferases | Q34208487 | ||
| Flow activates an endothelial potassium channel to release an endogenous nitrovasodilator | Q34209959 | ||
| The discovery of placenta growth factor and its biological activity. | Q34245619 | ||
| Cytomegalovirus infection impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine in transplant arteriosclerosis | Q34291030 | ||
| Placental protein 13 (PP-13): effects on cultured trophoblasts, and its detection in human body fluids in normal and pathological pregnancies. | Q34326623 | ||
| Increased autophagy in placentas of intrauterine growth-restricted pregnancies | Q34345453 | ||
| Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. | Q34385131 | ||
| Latest advances in understanding preeclampsia | Q34425288 | ||
| Uncovering the human methyltransferasome | Q34454874 | ||
| Placental apoptosis in health and disease. | Q34515113 | ||
| Lysine methylation and functional modulation of androgen receptor by Set9 methyltransferase | Q34609949 | ||
| First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction | Q34647428 | ||
| Emerging roles of post-translational modifications in signal transduction and angiogenesis | Q34978408 | ||
| Vascular endothelial growth factor receptors: molecular mechanisms of activation and therapeutic potentials. | Q35049227 | ||
| Development of glycoprotein capture-based label-free method for the high-throughput screening of differential glycoproteins in hepatocellular carcinoma | Q35098547 | ||
| A current concept of eclampsia | Q35156657 | ||
| Subclassification of preeclampsia | Q35196220 | ||
| Linking the epigenetic 'language' of covalent histone modifications to cancer | Q35670206 | ||
| Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome | Q35750283 | ||
| Differential expression of vascular endothelial growth factor (VEGF), endocrine gland derived-VEGF, and VEGF receptors in human placentas from normal and preeclamptic pregnancies | Q35764454 | ||
| Human protein arginine methyltransferase 7 (PRMT7) is a type III enzyme forming ω-NG-monomethylated arginine residues. | Q35868191 | ||
| Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia | Q35871381 | ||
| Apoptosis in the trophoblast--role of apoptosis in placental morphogenesis | Q35879137 | ||
| Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor | Q35909742 | ||
| Diagnosis and management of preeclampsia | Q35992738 | ||
| Circulating angiogenic factors in preeclampsia | Q36086665 | ||
| Endothelial cell dysfunction: can't live with it, how to live without it. | Q36093993 | ||
| Enzymatic mechanism and product specificity of SET-domain protein lysine methyltransferases | Q36557929 | ||
| Circulating and placental endoglin concentrations in pregnancies complicated by intrauterine growth restriction and preeclampsia | Q36772545 | ||
| A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a sma | Q36984261 | ||
| Chemical mechanisms of histone lysine and arginine modifications | Q37097824 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P921 | main subject | biomarker | Q864574 |
| vascular endothelial growth factor receptor 1 (VEGFR1) | Q24778444 | ||
| pregnant person | Q104720811 | ||
| pre-eclampsia | Q61335 | ||
| P304 | page(s) | 2632637 | |
| P577 | publication date | 2018-06-28 | |
| P1433 | published in | Journal of Pregnancy | Q26842466 |
| P1476 | title | Clinical Presentation of Preeclampsia and the Diagnostic Value of Proteins and Their Methylation Products as Biomarkers in Pregnant Women with Preeclampsia and Their Newborns | |
| P478 | volume | 2018 |
| Q90477254 | Intriguing Origins of Protein Lysine Methylation: Influencing Cell Function Through Dynamic Methylation |
| Q91610979 | Knowledge of preeclampsia and its associated factors among pregnant women: a possible link to reduce related adverse outcomes |
| Q91797584 | No association between early antiretroviral therapy during pregnancy and plasma levels of angiogenic factors: a cohort study |
Search more.